What’s Biosyent Inc. Downside After Today’s Huge Decline?

 What's Biosyent Inc. Downside After Today's Huge Decline?

The stock of Biosyent Inc. (CVE:RX) is a huge mover today! About 2,520 shares traded hands. Biosyent Inc. (CVE:RX) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.
The move comes after 8 months negative chart setup for the $111.96 million company. It was reported on Nov, 16 by Barchart.com. We have $6.92 PT which if reached, will make CVE:RX worth $14.55 million less.

Another recent and important Biosyent Inc. (CVE:RX) news was published by Midasletter.com which published an article titled: “Small Cap Discoveries Editor Paul Andreola on Lingo Media Corp, Biosyent Inc …” on January 19, 2016.

BioSyent Inc. is a specialty pharmaceutical company. The company has a market cap of $111.96 million. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has a 29.38 P/E ratio. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment